|
|
| | ceralifimod Basic information |
| Product Name: | ceralifimod | | Synonyms: | ceralifimod;Ceralifimod (Synonyms: ONO-4641);ONO-4641;3-Azetidinecarboxylic acid, 1-[[3,4-dihydro-6-[(2-methoxy-4-propylphenyl)methoxy]-1-methyl-2-naphthalenyl]methyl]-;Ceralifimod (ONO-4641) | | CAS: | 891859-12-4 | | MF: | C27H33NO4 | | MW: | 435.56 | | EINECS: | | | Product Categories: | | | Mol File: | 891859-12-4.mol |  |
| | ceralifimod Chemical Properties |
| Boiling point | 595.9±50.0 °C(Predicted) | | density | 1.172±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:5.0(Max Conc. mg/mL);11.48(Max Conc. mM) | | form | A crystalline solid | | pka | 2.71±0.20(Predicted) | | color | White to off-white |
| | ceralifimod Usage And Synthesis |
| Description | Ceralifimod is an agonist of the sphingosine-1-phosphate (S1P) receptors S1P1 and S1P5 (Kis = 0.626 and 0.574 nM, respectively). It is selective for S1P1 and S1P5 over S1P2-4 (Kis = >5,450, >5,630, and 28.8 nM, respectively). Ceralifimod induces calcium influx in CHO-K1 cells overexpressing S1P1 (EC50 = 1 nM) and cAMP accumulation in CHO-K1 cells overexpressing S1P1 or S1P5 (EC50s = 0.027 and 0.33 nM, respectively). In vivo, ceralifimod (0.03 and 0.1 mg/kg) reduces paw edema in a rat model of collagen induced arthritis (CIA). It also delays disease onset and inhibits lymphocyte infiltration of the spinal cord in a rat model of experimental autoimmune encephalomyelitis (EAE) and prevents disease relapse in a non-obese diabetic mouse model of relapsing-remitting EAE. | | storage | Store at -20°C |
| | ceralifimod Preparation Products And Raw materials |
|